Skip to main content

Table 2 Demographic information of the study cohort. There were no statistically significant differences between the two randomized groups in terms of the various clinical parameters. Results are presented as percentage with 95% confidence interval. H&H Hunt and Hess, SOFA sequential organ failure assessment score, HTN hypertension, DM diabetes mellitus, CKD chronic kidney disease

From: Low-chloride- versus high-chloride-containing hypertonic solution for the treatment of subarachnoid hemorrhage–related complications: The ACETatE (A low ChloriE hyperTonic solution for brain Edema) randomized trial

Parameter All (n = 59) Non-randomized (n = 27) NaCl (n = 15) NaCl/Na-acetate (n = 17)
Age 53.4 + 13.4 53.2 + 14.1 56.3 + 13.4 51.4 + 13.7
Gender (% female) 76.3% [64.3–85.7] 59.2% [40.6–76.1] 80% [55.6–94] 100%
H&H 1–2 44.1% [31.2–57.6] 66.7% [46.0–83.5] 20.0% [6.0–44.4] 29.4% [12.2–53.0]
H&H 3 39.0% [26.5–52.6] 29.6% [15.1–48.2] 66.7% [41.6–86.0] 29.4% [12.2–53.0]
H&H 4 15.3% [7.8–26.0] 3.7% [0.4–16.0] 13.3% [2.9–36.3] 35.3% [16.3–58.9]
H&H 5 1.7% [0.2–7.6]   0% 5.9% [0.6–24.4]
GCS on admit (median + IQR) 14 [11–15] 15 [13.5–15] 14 [7–15] 13 [7–15]
SOFA score on admit (median ± IQR) 1 [0–3] 1 [0–2] 2 [1–4.5] 2 [1–3]
HTN 47.5% [34.3–60.9] 40.7% [23.9–59.4] 53.3% [29.4–76.1] 52.9% [30.3–74.6]
CAD 6.8% [1.9–16.5] 3.7% [0.4–16.0] 13.3% [2.9–36.3] 5.9% [0.6–24.4]
DM 11.9% [4.9–22.9] 11.1% [3.2–26.8] 13.3% [2.9–36.3] 11.8% [2.5–32.7]
Smoker 47.5% [34.3–60.9] 55.6% [37.1–72.9] 40.0% [18.8–64.7] 41.2% [20.7–64.4]
CKD 1.7% [0.0–9.1] 0% 6.7% [0.7–27.2] 0%
EtOH abuse 10.2% [3.8–20.8] 14.8% [5.2–31.5] 6.7% [0.7–27.2] 5.9% [0.6–24.4]
Illicit drug use 25.4% [15.0–38.4] 29.6% [15.1–48.2] 6.7% [0.7–27.2] 35.3% [16.3–58.9]
First creatinine (mean ± SD) 0.80 + 0.31 0.82 + 0.27 0.79 + 0.26 0.76 + 0.42
Surgical approach to the aneurysm (% treated with endovascular approach) 69.5% [57..0–80.1] 81.5% [64.1–92.6] 66.7% [41.6–86.0] 52.9% [30.3–74.6]